Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate

Poupart, M C; Chanal, C.; Sirot, D.; Labia, Roger; Sirot, J.

doi:10.1128/aac.35.7.1498

Cited by 32 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, multidrug resistance, with rates of resistance to these antimicrobial agents of more than 50%, has been reported in many areas of the world (35,45,124,137). Extended-spectrum cephalosporins and fluoroquinolones have been suggested as appropriate alternative agents in the treatment of infections caused by such multidrug-resistant Salmonella serotypes (10,22,64); however, since 1991, outbreaks or cases of infections caused by Salmonella serotypes resistant to extended-spectrum cephalosporins or fluoroquinolones have been increasingly reported (9,16,21,23,35,61,62,90,114,128).…”

Section: Antimicrobial Resistance Epidemiologymentioning

confidence: 99%

“…A variety of such ␤-lactamases have been described in Salmonella, most of which are cefotaxime-hydrolyzing ␤-lactamases (CTX-M types) (9,16,21,61,62,114,128) or CMY-2 AmpC ␤-lactamases that could hydrolyze cephalosporins as well as cephamycins (23,90). The genes encoding extended-spectrum ␤-lactamases could be carried by conjugative plasmids, transposons, or integrons.…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

See 1 more Smart Citation

Salmonella entericaSerotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment

2004

View full text Add to dashboard Cite

SUMMARY Nontyphoid Salmonella strains are important causes of reportable food-borne infection. Among more than 2,000 serotypes, Salmonella enterica serotype Choleraesuis shows the highest predilection to cause systemic infections in humans. The most feared complication of serotype Cholearesuis bacteremia in adults is the development of mycotic aneurysm, which previously was almost uniformally fatal. The advances in diagnostic techniques, surgical care, and antimicrobial therapy have greatly improved the survival of these patients. However, the recent emergence of serotype Choleraesuis that is resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and, notably, fluoroquinolone antibiotics has aroused concern about the use of these agents for the empirical treatment of systemic infection caused by this organism. In view of the serious implications of the situation, the chain of transmission and mechanism of resistance should be carefully studied to reduce the spread of infection and threat to human health. To date, there are no vaccines available to prevent serotype Choleraesuis infections in humans. The availability, in the near future, of the genome sequence of serotype Cholearesuis will facilitate the development of effective vaccines as well as the discovery of new targets for novel antimicrobial agents.

show abstract

Section: Antimicrobial Resistance Epidemiologymentioning

confidence: 99%

Section: Mechanisms Of Resistancementioning

confidence: 99%

Salmonella entericaSerotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment

2004

View full text Add to dashboard Cite

show abstract

“…In North Africa, SHV-2 has been reported in Salmonella serotypes Wien (25), Typhimurium (22), and Mbandaka (27), TEM-3 has been reported in Salmonella serotype Typhimurium (1), CMY-2 has been reported in Salmonella serotype Senftenberg (31), and ACC-1 has been reported in Salmonella serotype Livingstone (43). Only TEM-25 and SHV-2 have been reported in Salmonella serotype Mbandaka (27,41).…”

mentioning

confidence: 99%

“…Over the past 2 decades and particularly in developing countries, Salmonella strains resistant to broad-spectrum cephalosporins have been reported (30). These strains produce extended-spectrum ␤-lactamases (ESBLs), such as TEM and SHV (TEM-3, TEM-4, TEM-25, TEM-27, SHV-2, and SHV-5) (1,4,7,8,16,18,22,25,33,41,42), CTX-M-2 (10, 23), CTX-M-3 (7), PER-1 (46), and PER-2 (11) and, more recently, plasmid-mediated AmpCtype enzymes, such as DHA-1 (21), CMY-2 (19,20,31,35,(47)(48)(49), and ACC-1 (43). In North Africa, SHV-2 has been reported in Salmonella serotypes Wien (25), Typhimurium (22), and Mbandaka (27), TEM-3 has been reported in Salmonella serotype Typhimurium (1), CMY-2 has been reported in Salmonella serotype Senftenberg (31), and ACC-1 has been reported in Salmonella serotype Livingstone (43).…”

mentioning

confidence: 99%

Molecular Epidemiology and Characterization of Plasmid-Encoded β-Lactamases Produced by Tunisian Clinical Isolates of Salmonella enterica Serotype Mbandaka Resistant to Broad-Spectrum Cephalosporins

2003

View full text Add to dashboard Cite

We studied 31 clinical isolates of Salmonella enterica serotype Mbandaka resistant to broad-spectrum cephalosporins and recovered in Tunisia over a 5-year period. The transferability of this resistance was demonstrated by conjugation experiments. Thirty of the 31 isolates were positive in the double-disk synergy test. By isoelectric focusing analysis, all of the isolates were found to produce a band of ␤-lactamase activity with a pI of 5.9. Three of these isolates produced an additional band with a pI of 7.6. PCR and DNA sequencing identified these ␤-lactamases as TEM-4 and SHV-2a, respectively. The remaining isolate, highly resistant to ceftazidime but susceptible to cefepime, produced a ␤-lactamase that focused at pI 7.8. No synergy was detected by the double-disk synergy test. Sequence analysis of the bla gene amplified by PCR showed that the plasmidmediated AmpC-type enzyme was ACC-1a. Fingerprinting analysis by repetitive-element PCR and enterobacterial repeat intergenic consensus-PCR suggested that 29 of the 31 Salmonella serotype Mbandaka isolates belonged to the same clonal population.

show abstract

“…No resistance was observed, and we consider these agents to be very good alternatives for clinical treatment. However, resistance to extended-spectrum cephalosporins (3,5,20,25) and resistance or diminished susceptibility to quinolones (8,12,23,24) have been described for salmonellae, and this fact is of concern for public health. The genes encoding the new plasmid-mediated ,B-lactamases with a spectrum of activity extending to include most of the extended-spectrum cephalosporins are derived from point mutations of the genes encoding the common enzymes TEM-1, TEM-2, and SHV-1 (15).…”

mentioning

confidence: 99%

Susceptibilities of ampicillin-resistant strains of Salmonella other than S. typhi to 10 antimicrobial agents

Alós

Gómez-Garcés

Cogollos

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Ampicillin-resistant strains of Salmonella other than S. typhi constitute a health problem. We tested the antimicrobial susceptibilities to 10 antibiotics of 57 of these strains isolated in a 30-month period. The rates of resistance were as follows: chloramphenicol, 40.3%; tetracycline, 33.3%; gentamicin, 5.3%; co-trimoxazole, 5.3%; nalidixic acid, 1.8%; and amoxicillin-clavulanic acid, cefotaxime, ceftriaxone, aztreonam, and ciprofloxacin, 0%. In our experience, there are alternative antibiotics with excellent in vitro activities.

show abstract

Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate

Cited by 32 publications

References 12 publications

Salmonella entericaSerotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment

Salmonella entericaSerotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment

Molecular Epidemiology and Characterization of Plasmid-Encoded β-Lactamases Produced by Tunisian Clinical Isolates of Salmonella enterica Serotype Mbandaka Resistant to Broad-Spectrum Cephalosporins

Susceptibilities of ampicillin-resistant strains of Salmonella other than S. typhi to 10 antimicrobial agents

Contact Info

Product

Resources

About